Are we there yet? The holy grail: A biomarker for Multiple Sclerosis

Affiliations

¹ John Hunter Hsopital, Hunter New England Local Health District, Newcastle, Australia; Immune Health Program, Hunter Medical Research Institute, Newcastle, Australia. Electronic address: Jeannette.LechnerScott@health.nsw.gov.au.
² John Hunter Hsopital, Hunter New England Local Health District, Newcastle, Australia; Immune Health Program, Hunter Medical Research Institute, Newcastle, Australia.
³ Department of Neurology, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, United Kingdom.
⁴ Department of Neuroimmunology, Queen Mary University of London, United Kingdom.
⁵ Department of Neuroimmunology, Massachusetts General Hospital, Havard Medical School, Boston, USA.
⁶ Department of Paediatrics (Neurology), The Hospital for SickKids, University of Toronto in Ontario, Canada.

Editorial

Jeannette Lechner-Scott et al. Mult Scler Relat Disord. 2023 Oct.

. 2023 Oct:78:104998.

doi: 10.1016/j.msard.2023.104998. Epub 2023 Sep 12.

¹ John Hunter Hsopital, Hunter New England Local Health District, Newcastle, Australia; Immune Health Program, Hunter Medical Research Institute, Newcastle, Australia. Electronic address: Jeannette.LechnerScott@health.nsw.gov.au.
² John Hunter Hsopital, Hunter New England Local Health District, Newcastle, Australia; Immune Health Program, Hunter Medical Research Institute, Newcastle, Australia.
³ Department of Neurology, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, United Kingdom.
⁴ Department of Neuroimmunology, Queen Mary University of London, United Kingdom.
⁵ Department of Neuroimmunology, Massachusetts General Hospital, Havard Medical School, Boston, USA.
⁶ Department of Paediatrics (Neurology), The Hospital for SickKids, University of Toronto in Ontario, Canada.

No abstract available

Publication types